282 results about "Senescence" patented technology

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The invention discloses a gene RhNADP-LIKE for regulating and controlling Chinese rose flower aging, and particularly relates to the technical field of molecular biology and horticultural plant physiology. According to the invention, bottle insertion life phenotype data of 358 parts of core germplasm of tetraploid Chinese rose is screened through genome-wide association analysis (GWAS), and the gene RhNADP-LIKE significantly associated with senescence is identified. The gene accelerates the aging process of petals by regulating the accumulation of reactive oxygen species (ROS). After RhNADP-LIKE expression is inhibited by using a virus-induced gene silencing (VIGS) technology, the blooming period of rosa chinensis flowers is prolonged by about 2 days, and the ROS level is remarkably reduced. The invention provides a molecular target for prolonging the vase life of the Chinese rose, can be applied to gene editing breeding or development of an environment-friendly preservative, reduces the dependence of chemical agents, and improves the economic benefit and sustainable development potential of the cut flower industry.

The invention discloses lactobacillus crispatus for relieving senescence by promoting collagen synthesis and a metagen of the lactobacillus crispatus, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 metagen provided by the invention has a good skin anti-aging effect, the content of collagen is increased, meanwhile, the skin moisture can be increased, and the skin oxidation resistance can be improved. Specifically, the enzyme activity of MMP-3 and MMP-1 of HSF cells can be inhibited in vitro by thallus lysate, and the content of COL I and COL III and the enzyme activity of LH1 can be improved in vitro from fermentation of supernate; the enzyme activity of MMP-1 and MMP-3 can be inhibited by orally taking inactivated thalli; the self-fermented supernate is orally taken, so that the enzyme activity of LH1 and LOX can be improved, the enzyme activity of MMP-3 can be reduced, and the anabolism of collagen can be regulated and controlled.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses an anti-aging and anti-fatigue traditional Chinese medicine formula and a preparation method thereof. The traditional Chinese medicine formula comprises the following raw materials in parts by weight: 10-12 parts of ginseng, 10-15 parts of rhodiola rosea, 8-10 parts of dendrobium officinale, 5-6 parts of turmeric, 5-8 parts of cordyceps militaris, 8-10 parts of radix puerariae, 6-10 parts of schisandra chinensis, 1-3 parts of liquorice, 8-10 parts of lycium ruthenicum, 8-10 parts of cistanche, 10-12 parts of acanthopanax and 8-10 parts of phellinus igniarius. The adaptive capacity of an organism to an anoxic environment is improved, fatigue is effectively relieved, and various active ingredients contained in the health-care food contribute to delaying the senescence process.

The invention relates to a phenylacetylglutamine / phenylacetylglycine induced vascular smooth muscle cell senescence model and an establishment method and application thereof, and belongs to the technical field of cell models.The method comprises the following steps that vascular smooth muscle cell suspension is placed in a porous plate, 10% of FBS and 1% of mycillin are added into a culture medium, 24 h after cells adhere to the wall, the vascular smooth muscle cell senescence model is obtained, and the vascular smooth muscle cell senescence model is obtained. The method comprises the following steps of: adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into a porous plate, changing a serum-free culture medium, continuously culturing for 24 hours, adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into the porous plate, changing the culture medium added with phenylacetyl glutamine or phenylacetyl glycine once every 24 hours, and collecting cells after 72 hours. According to the invention, phenylacetylglutamine / phenylacetylglycine is used for inducing and establishing the vascular smooth muscle cell senescence model for the first time, the method is easy to operate and low in cost, and a foundation is laid for researching the relationship between cardiovascular diseases and senescence.

The invention discloses an application of interaction of a pear transcription factor PbrDDI2 and a PbrAPX14 gene promoter in regulation and control of maturation and senescence of pear fruits. The nucleotide sequence of the pear transcription factor PbrDDI2 is as shown in SEQ ID NO.1 in a sequence table, and the amino acid sequence of the gene coded protein is as shown in SEQ ID NO.2. The invention discloses the transcription factor PbrDDI2 for regulating and controlling the PbrAPX14 gene expression of the pear fruit for the first time. The invention clarifies an action mechanism of interaction of cis-acting elements (TTTGTCG / CGACAAA) in PbrDDI2 and PbrAPX14 gene promoters in clearing endogenous H2O2 accumulation and further inhibiting synthesis of ethylene so as to inhibit fruit ripening and senescence, and provides a theoretical and practical basis for cultivating anti-senescence high-quality pear varieties.

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.

The invention discloses a method for extracting an anti-aging component camellia saponin A from camellia on the basis of a full-bionic targeted extraction technology and application of the anti-aging component camellia saponin A. Efficient enrichment and structure protection of the camellia saponin A are achieved by simulating the whole process of decomposition and absorption of the oral cavity, the stomach and the intestinal tract of a human body. Specifically, the camellia flowers or leaves are pretreated through supercritical extraction, lipid and gel impurities which are contained in the camellia flowers or leaves and are prone to forming gelatinoids are removed, and convenience is provided for subsequent purification; the problems that the camellia saponin A is low in yield and easy to degrade are solved by applying a full-bionic enzymolysis technology, and meanwhile, impurities such as lipid, protein, tannin and sugar can be degraded through full-bionic extraction, so that convenience is provided for subsequent crystallization; and purifying by adopting a macroporous resin adsorption technology, and finally purifying by crystallization. The camellia saponin A obtained by the invention can better achieve the effects of improving wrinkles, repairing skin, brightening skin color and delaying senescence through multi-way and multi-azimuth anti-wrinkle, repairing and whitening effects, and can be widely applied to various types of cosmetics.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for improving and treating cognitive impairment. The invention discloses the new application of the rhamnosus cheese for the first time, and the rhamnosus cheese can improve or treat cognitive impairment related to aging by improving behavioral function change, brain inflammatory factors, oxidative stress activity and neurotransmitter level caused by aging of mice and regulating transcriptome, intestinal microbiome, metabolome and the like. The lactobacillus rhamnosus has a potential application prospect in the aspect of improving learning and memory ability impairment caused by senescence.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The invention relates to a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist for use in a method of treating a patient suffering from a tumour. The invention further relates to a pharmaceutical composition, comprising a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumour, and to a calcium homeostasis disruptor in combination with a selective DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.

The invention relates to health-preserving conditioning tea and a preparation method thereof, and belongs to the technical field of tea drinks, and the health-preserving conditioning tea comprises a paederia scandens extract, a radix fici simplicissimae extract, a Chinese yam-eclipta alba distilled liquid medicine and an angelica sinensis extract. The prepared health-preserving conditioning tea can help human body aging. Meanwhile, ovarian senescence can be delayed, and the ovarian health state can be improved.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.

The application discloses RhALEU protein and an application of an encoding gene thereof in regulation of old age of rose petals. RhALEU The application screens out a gene from a rose transcriptome database RhALEU , and finds that expression of the gene is induced in the whole petal development stage. RhALEU The application verifies that the gene has a function of promoting old age of rose petals by using VIGS technology. RhALEU Silencing of the gene slows down the speed of the petal from the 5th grade to losing ornamental value. RhALEU In the petal with the silenced gene, expression of the old age related gene SAG12 is significantly down-regulated. RhALEU The application discloses the function of the gene in natural old age of the petal, provides a new thought and technical means for regulating old age of a plant flower, especially postharvest preservation of fresh cut rose, opens up a new research field of flower regulation, and has great academic value and important production application prospect.

The invention discloses a reverse-age anti-aging traditional Chinese medicine compound composition containing 2-oxoglutaric acid and a preparation method of the reverse-age anti-aging traditional Chinese medicine compound composition. The composition comprises ganoderma lucidum peptide, astragalus peptide, ginseng peptide, 2-oxoglutaric acid, gamma-aminobutyric acid, rehmannia, cistanche, Chinese yam, rhizoma polygonati, honeysuckle, dendrobium officinale and turmeric. The ganoderma lucidum peptide, the astragalus peptide, the ginseng peptide and other components cooperate with one another, so that free radicals can be removed, oxidation reaction can be inhibited, cell membranes can be stabilized, cell oxidative damage can be reduced, and senescence can be delayed. Components such as honeysuckle and turmeric can inhibit inflammation signal channels and reduce inflammatory factors, dendrobium officinale can regulate inflammatory cells, and astragalus membranaceus peptide and ginseng peptide can enhance immunity and reduce inflammatory hazards. In the cellular level, 2-oxoglutaric acid is used for supplying energy and regulating genes, and gamma-aminobutyric acid is used for improving sleep and promoting repair; on the whole, the multiple components can tonify vital qi, nourish viscera, improve qi and blood and improve skin and mental states. Through cooperation of multiple aspects, the disease risk is reduced.

The present application relates to a system for assessing the degree of senescence, which assesses the degree of senescence of a cell by calculating a score of a cell metabolome state by taking into account metabonomics data of the cell. The system is especially suitable for cosmetic efficacy evaluation, anti-aging drug screening and other scenes, can shorten the research and development period in practical application, and has significant industrial application value.

The invention relates to a Saccharomyces cerevisiae C16I09 strain which is preserved in the China Center for Type Culture Collection on May 21, 2025, and the preservation number of the Saccharomyces cerevisiae C16I09 strain is CCTCC (China Center for Type Culture Collection) No. M20251150. The strain disclosed by the invention has good oxidation resistance and can be applied to the fields of skin care products, health care products, anti-aging foods and the like. Especially, extracellular fermentation broth of the strain, namely a fermentation product or a fermentation extract of the strain, has excellent oxidation resistance, can scavenge free radicals and relieve oxidative damage, has the effects of protecting skin, resisting inflammation, delaying senescence and the like, and can be applied to the fields of skin care products, health care products, anti-aging foods and the like as a natural anti-aging agent.

The invention provides a gene marker combination and system for predicting glioma risk and application, and belongs to the technical field of glioma prediction. The gene marker combination comprises an NTN4 gene, an RBP1 gene, a TWIST1 gene, a GADD45G gene, an NUAK2 gene, a GRIK2 gene, a WEE1 gene and an RRM2 gene. Eight senescence-related genes are screened by screening senescence-related genes and combining survival data of glioma patients. The research finds that the risk scoring model constructed by using the eight senescence-related genes can specifically and sensitively predict the glioma risk, and has good prediction efficiency. According to the method, the glioma risk assessment model constructed on the basis of combining the risk scoring model with the clinical pathological variable factors is established, and compared with the capability of predicting the glioma risk of the risk scoring model, the glioma risk assessment model is better in prediction efficiency.

The invention relates to the technical field of collagen intelligent monitoring, and particularly discloses an intelligent collagen monitoring method and system integrated with a microsensor. Enzyme response hydrogel with switchable states is anchored to the skin through a microneedle array, a high-frequency acoustic impedance analysis module is used for continuously probing the acoustic impedance change of the hydrogel, and the collagen monitoring accuracy is improved. Identifying a collagen degradation event; once collagen degradation is detected, the system activates the micro-regeneration unit, a cleaning solution and a regeneration solution are conveyed through a microfluidic channel, a broken peptide chain is removed, a hydrogel cross-linked network is reconstructed, and functional regeneration of the sensing unit is realized; the system further comprises a regeneration state confirmation and cycle reset mechanism, and the reliability of each monitoring cycle and the consistency of data references are ensured. According to the method, the limitation of a traditional monitoring method is overcome, multiple times of recycling of a single sensor is achieved, the credibility and consistency of long-term monitoring data are improved, and the method has important significance on skin health management and senescence research.

The invention discloses an exosome as well as a preparation method and application thereof, and belongs to the technical field of exosomes. The preparation method comprises the following steps: step 1, intermittently immersing and culturing a sterile tissue to obtain a concentrated solution of the exosome I; step 2, collecting the cultured sterile tissues, and performing ultrasonic-assisted extraction to obtain a purified crude extract II; and 3, purifying the concentrated solution obtained in the step 1 and the purified crude extract 2 obtained in the step 2 by size exclusion chromatography to obtain the pure exosome. The exosome obtained by the invention is applied to preparation of cosmetics, health-care foods or medicines for inhibiting skin cell senescence. According to the preparation method disclosed by the invention, impure proteins and non-target particles are effectively removed, the purity of the exosome is improved, the structural integrity of the exosome is kept, false exosome impurities generated by a traditional crushing method are avoided, the yield of the exosome is improved by 3-5 times, and a reliable material basis is provided for subsequent functional research of the exosome.

The invention discloses a pharmaceutical composition with skin repairing, anti-inflammatory and anti-aging effects as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition mainly comprises a stem cell exosome and a fusion polypeptide-single domain antibody conjugate, and can also comprise proline and pharmaceutically acceptable auxiliary materials. The amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO.1, and the fusion polypeptide can specifically target skin cells; the single-domain antibody is an anti-IL-6 single-domain antibody, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO.2, and the single-domain antibody can efficiently inhibit inflammatory factors. Experiments show that through the synergistic effect of all the components, the composition remarkably promotes proliferation of skin fibroblasts and keratinocytes, inhibits secretion of inflammatory factors such as IL-6 and TNF-alpha, promotes synthesis of collagen, effectively improves skin aging and inflammation states and has wide application prospects in the fields of skin repair, inflammation resistance and senescence resistance.

The invention discloses a composition for improving immunity and delaying senescence and a preparation method thereof. Belongs to the technical field of functional health. The composition comprises the following components in parts by mass: 5-50 parts of collagen, 10-80 parts of paeonia ostii tea, 1-20 parts of an antioxidant, 3-10 parts of an intestinal microecology regulator and 1-3 parts of an energy metabolism and nerve regulator. According to the invention, through multi-system cooperation and multi-target intervention, dual effects of immune enhancement and senescence delay are realized. Through scientific compounding and a special process, the product has the advantages of stable components, uniform activity and good solubility. Animal experiments and theoretical models show that immune organs can be effectively protected, accumulation of aging markers is reduced, and a solution is provided for development of comprehensive anti-aging health products.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and / or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and / or protein replacement, or a combination thereof using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.

The invention discloses a fresh-keeping storage method of plum fruits, which is characterized in that a compact network structure of a shellac-pullulan-gellan gum basic composition effectively obstructs invasion of external microorganisms, and significantly slows down loss of water in the fruits, so that the plump appearance and hardness of the fruits are maintained, and the fruit quality is improved. The siRNA and the AVG wrapped by the lipidosome accurately interfere with the ripening and senescence process in the fruit from the molecular level, the siRNA specifically silences the gene expression of cell wall degradation key enzyme and delays the softening process of the fruit, and the AVG effectively blocks the biosynthesis pathway of ethylene and inhibits the start of an after-ripening signal, so that the ripening and senescence process of the fruit is delayed. The external formed physical film provides a stable microenvironment for internal bioactive molecules, protects the internal bioactive molecules from being degraded and prolongs the action time, and the internal molecular regulation delays the disintegration of cell structures, so that the external film can be attached more enduringly and exerts a barrier function, and the maintenance of the fruit quality is realized under a refrigeration condition.

The invention relates to a mesenchymal stem cell serum-free culture medium with limited chemical components as well as application and a method thereof, the serum-free culture medium is completely serum-free and has definite components: all additives are known chemical substances and meet the production requirements of cGMP (Complementary Good Manufacturing Practice); telomere shortening can be obviously delayed; replicative senescence is slowed down by activating TERT expression; the multiplication capacity can also be enhanced; the P10 generation cells still have the active division capacity; multidirectional differentiation is supported; the osteogenic differentiation efficiency is superior to that of a traditional serum-containing system; and the method is suitable for industrial production and clinical transformation.

The application discloses application of falcarinol-7-methyl ether and derivatives thereof in preparation of medicines and functional foods for delaying aging or immune regulation. In the application, the falcarinol-7-methyl ether and derivatives thereof are derived from falcarinol-7-methyl ether, and can effectively delay replicative senescence of mesenchymal stem cells, inhibit expression of aging-related markers of mouse liver and lung induced by adriamycin, improve grip strength of the mouse, enhance muscle function, and promote proliferation of T cells separated from human peripheral blood mononuclear cells, and have an immune regulation effect. Therefore, the falcarinol-7-methyl ether and derivatives thereof have good effects of improving telomerase activity, anti-aging and immune regulation, and can be developed into anti-aging or immune regulation products.

The invention relates to novel oligonucleotides and their use in inhibiting or reducing senescence. The oligonucleotides target specific sequences in the 3' untranslated region (UTR) of heterogeneous nuclear ribonucleoprotein D (HNRNPD) mRNA and blocks one or more inhibitory microRNA (miRNA) binding sites. This promotes the physiologically regulated expression of HNRNPD and reduces senescence.

The invention discloses an application of a small molecular compound and an analogue thereof in treating ovarian aging diseases. It is found for the first time that the exogenous supplementary adenosine or the analogues thereof can effectively recover or improve the ovarian function and can prevent and inhibit ovarian fibrosis, and therefore the exogenous supplementary adenosine or the analogues thereof can be used as potential drugs for recovering the female fertility.